ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 2457 • ACR Convergence 2025

    Maternal, Embryo-Fetal And Neonatal Outcomes Following Belimumab Exposure During Pregnancy In Patients With Systemic Lupus Erythematosus

    Kenza El Ouazzani1, Nathalie Morel1, Delphine Beghin2, Gaelle GUETTROT-IMBERT3, Noémie JOURDE-CHICHE4, Alban DEROUX5, Françoise Sarrot-Reynauld5, Lionel Couzi1, Vincent Langlois6, Estibaliz LAZARO7, Pauline ORQUEVAUX8, Benjamin DE SAINTE MARIE9, Kevin Deve10, christophe Deligny11, Nicole Ferreira12, Bertrand Godeau13, Véronique Le Guern3, Raphaelle Meunier14, Elisabeth Pasquier15, Viviane Queyrel Moranne16, Laurent Sailler17, Cécile Saint-Pastou18, Nathalie Costedoat-Chalumeau3, Benoit Marin19 and Christophe Richez1, 1Bordeaux University Hospital, Bordeaux, France, 2Paris Pitié-Salpêtrière Hospital, Paris, France, 3Cochin Hospital, Paris, France, 4Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France., Marseille, France, 5Grenoble university hospital, Grenoble, France, 6Le Havre University Hospital, Le Havre, France, 7Bordeaux University Hospital, Pessac, France, 8Reims University Hospital, Reims, France, 9Timone university hospital, Marseille, France, 10Bayonne hospital, Bayonne, France, 11Fort-de-France hospital, Fort-de-France, France, 12Tours University Hospital, Tours, France, 13Creteil Hospital, Paris, France, 14Libourne Hospital, Libourne, France, 15Brest University Hospital, Brest, France, 16Nice University Hospital, Nice, France, 17CHU Toulouse, Toulouse, France, 18Saint-Pierre Hospital, Saint-Pierre, France, 19Hôpital Pitié-Salpêtrière, Paris, France

    Background/Purpose: Systemic lupus erythematosus (SLE) may be associated with high-risk pregnancies, especially in the presence of specific predisposing factors. While optimal disease control during pregnancy…
  • Abstract Number: 2439 • ACR Convergence 2025

    Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis

    Ahmad Alomari1, Nikita Shah2, Miguel Rodriguez3 and Diala Alawneh4, 1UCF- North Florida hospital, Gainesville, FL, 2UCF/HCA Florida North Florida Hospital, Gainesville, FL, 3SIMED Rheumatology, Gainesville, FL, 4University of Florida, Gainesville, FL

    Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), often leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD).…
  • Abstract Number: 2420 • ACR Convergence 2025

    In-patient Outcomes of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome in SLE: US National Inpatient Database (2021-2022)

    Nattanicha Chaisrimaneepan1, Pitchaporn Yingchoncharoen2 and Miriam Paz2, 1Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, 2Texas Tech University Health Sciences Center, Lubbock

    Background/Purpose: Systemic lupus erythematosus (SLE is an autoimmune disease that attacks different organs. There have been reports of hyperglycemic hyperosmolar syndrome (HHS) from steroid use…
  • Abstract Number: 2403 • ACR Convergence 2025

    Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis

    Jaime Flores-Gouyonnet1, Erika Navarro-Mendoza1, Mario Bautista-Vargas1, Ali Ardekani1, Maria Cuellar-Gutierrez1, Gabriel Figueroa-Parra2, Mariana Gonzalez-Treviño3, Alain Sanchez-Rodriguez4, Andrew C. Hanson1, Cassondra Hulshizer5, Cynthia Crowson6 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 3Vanderbilt University Medical Center, Nashville, TN, 4ABC Medical Center, Ciudad de México, Federal District, Mexico, 5Mayo Clinic, Rochester, 6Mayo Clinic, Stewartvillle, MN

    Background/Purpose: SLE is clinically heterogeneous and associated with increased hospitalizations. However, it remains unclear which patient subgroups drive this excess in unplanned healthcare use. We…
  • Abstract Number: 2385 • ACR Convergence 2025

    The Presence of Avascular Necrosis in Patients with Systemic Lupus Erythematosus Undergoing Total Knee Arthroplasty is Not Associated with Worse Outcomes

    Billy Kim1, Ahmed Deeb1, Douglas Mintz1, Susan Goodman2, Jose Rodriguez2, Mark Figgie2 and Jason Blevins3, 1Hospital for Special Surgery, New York, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, New York, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) patients seeking total knee arthroplasty (TKA) may present with secondary avascular necrosis (AVN) of the knee due to high-dose glucocorticoid…
  • Abstract Number: 2220 • ACR Convergence 2025

    Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases

    Rashmi Dhital1, Kerri Bertrand2, Dilli Poudel3, Christina Chambers4 and Monica Guma2, 1Vanderbilt University Medical Center, Brentwood, TN, 2University of California San Diego, San Diego, CA, 3Vanderbilt University Medical Center, Nashville, TN, 4University of California, San Diego, La Jolla, CA

    Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are characterized by chronic systemic inflammation and often require…
  • Abstract Number: 1989 • ACR Convergence 2025

    Moving Out of the Kid’s Rheum: Transitioning Young Adult Patients from Pediatric to Adult Rheumatology Practices

    Victoria Koenigsberger1, Madeleine Ward2, Meghan Geary3 and Ali Yalcindag4, 1The Warren Alpert Medical School of Brown University, Providence, RI, 2The Warren Alpert Medical School of Brown University, Division of Medicine-Pediatrics, Providence, 3The Warren Alpert Medical School of Brown University, Division of General Internal Medicine, Providence, 4The Warren Alpert Medical School of Brown University, Division of Rheumatology, Department of Pediatrics, Milton, MA

    Background/Purpose: Young adults with childhood-onset rheumatic conditions encounter challenges and barriers to care when transitioning to an adult rheumatologist. At this Pediatric Rheumatology Clinic, patients…
  • Abstract Number: 1878 • ACR Convergence 2025

    Customized Therapy for SLE: How Disease Severity Influences the Use of Corticosteroids and Biologics in Patients with SLE in the Lupus Federated Data Network (LupusNet) and a US Claims Database

    Ashley Orillion1, Federico Zazzetti2, Anna Sheahan3, Clair Blacketer1, Michel van Speybroeck4, Sarah Gasman1, Reyhan Sonmez5, Erika Noss1, Manuel Ugarte-Gil6, Rocío Gamboa-Cárdenas7, Víctor Pimentel-Quiroz8, Kaleb Michaud9, Patti Katz10, Rangi Kandane-Rathnayake11, Eric Morand12, Worawit Louthrenoo13, Alberta Hoi14, Yi-Hsing Chen15, Jiacai Cho16, Laniyati Hamijoyo17, Shue Fen Luo18, Sandra Navarra19, Mandana Nikpour20, José María Pego-Reigosa21, Iñigo Rúa-Figueroa22, Zulema Plaza23, María Galindo-Izquierdo24, Julia Martínez Barrio25, Jaime Calvo26, Antonio Fernández-Nebro27, Raúl Menor Almagro28, EVA GLORIA TOMERO MURIEL29, Javier Narváez30 and Chetan S. Karyekar31, 1Johnson & Johnson, Spring House, PA, USA, Spring House, PA, 2Johnson & Johnson, Horsham, PA, USA, Ambler, PA, 3Johnson & Johnson, Horsham, PA, USA, Horhsam, PA, 4Johnson & Johnson, Beerse, Belgium, Beerse, Belgium, 5Capgemini Consulting, Zurich, Switzerland, Zurich, Switzerland, 6Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, 7Universidad Científica del Sur, Lima, Peru, 8Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Perú; Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Perú, Lima, Peru, 9University of Nebraska Medical Center, Omaha, NE, 10UCSF, San Rafael, CA, 11Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, 12Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, 13Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, Chiang Mai, Thailand, 14Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, 15Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Taichung, Taiwan (Republic of China), 16National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, Singapore, Singapore, 17Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, Badung, Indonesia, 18Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan, Taoyuan, Taiwan (Republic of China), 19University of Santo Tomas, Manila, Philippines, 20University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia, 21Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, 22Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, 23Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, 24Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, Madrid, Madrid, Spain, 25Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, 26Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, 27Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, 28Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, 29Hospital Universitario de la Princesa, Madrid, Spain, 30Hospital Universitario de Bellvitge, Barcelona, Spain, 31Johnson & Johnson, Spring House, PA, USA, Spring House

    Background/Purpose: The management of SLE varies worldwide. Current SLE treatment goals focus on preventing flares, controlling disease activity, and preventing organ damage accrual. LupusNet is…
  • Abstract Number: 1837 • ACR Convergence 2025

    Enhanced Mitochondrial Activity in B cells from Females Is Required to Drive Increased T-bet Induction by TLR7 in Lupus

    John D. Mountz1, Kathryn Sullivan2, Shanrun Liu2, Cynthia Liu2, Min Gao2, Walter Winn Chatham3, Tanecia Mitchell2 and Hui-Chen Hsu2, 1University Alabama Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Nevada, Las Vegas, Las Vegas, NV

    Background/Purpose: Systemic lupus erythematosus (SLE) is a predominantly female autoimmune disease, with a 9:1 female-to-male ratio. Our previous studies indicated that increased T-bet+ age-related B…
  • Abstract Number: 1743 • ACR Convergence 2025

    Comparative assessment of cardiovascular risk and its predictors in a large cohort of young adults with juvenile systemic lupus erythematosus and juvenile dermatomyositis

    Jiangning Li, Shreya Doddi, Tharuni Mailoo and Coziana Ciurtin, University College London, London, United Kingdom

    Background/Purpose: Juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM) are associated with chronic inflammation that can accelerate atherosclerosis. There is no specific guidance regarding…
  • Abstract Number: 1690 • ACR Convergence 2025

    Environmental Heat Exposure and Risk of Systemic Lupus Erythematosus

    Jennifer Woo1, Kaitlyn Lawrence2 and Dale Sandler1, 1National Institute of Environmental Health Sciences, Durham, NC, 2DLH, Corp., Durham, NC

    Background/Purpose: Environmental heat exposures have been linked to increased morbidity and mortality. Individuals with systemic lupus erythematous (SLE) often have heat- and photo- sensitivity, which…
  • Abstract Number: 1548 • ACR Convergence 2025

    Anifrolumab In Systemic Lupus Erythematosus. Spanish Multicenter Registry In Clinical Practice

    Vanesa Calvo-Río1, Carmen Secada-Gómez1, Miriam Retuerto Guerrero2, Judit Font-Urgelles3, Ivette Casafont-Solé3, Adrián Mayo-Juanatey4, Juan José Alegre-Sancho5, DALIFER FREITES6, Cristina Hormigos Martin7, Noemí Garrido8, GUILLERMO GONZALEZ ARRIBAS9, Juan Roberto Miguelez Sanchez10, Andrea García-Valle11, Marta Ibañez12, Fernando Lozano Morillo13, Ángel García Manzanares14, Sebastián Sandoval-Moreno15, Josefina Cortés-Hernández16, Deseada Palma-Sanchez17, LETICIA LOJO-OLIVEIRA18, Evelin Cervantes19, Paz Collado Ramos20, cristina arciniega Larios21, Luis Sala22, Eztizen Labrador-Sánchez23, Cilia Peralta-Ginés24, Nahia Plaza-Aulestia25, Irati Urionaguena Onaindia26, Miguel Medina Malone27, Jose Rosas Gómez de Salazar28, Montserrat Corteguera29, Laura Cebrian30, Fred Anton Pages31, Jose Ramón Lamua-Riazuelo32, María Dolores Fábregas Canales33, María José Alados Hernández34, Marta Garijo Bufort35, Anna Pamies36, Luis Sarabia37, Rodrigo Aguirre-del-Pino38, José Ángel Cabezas Lefler39, alvaro seijas38, Carmen Carrasco-Cubero40, Ana López-Cerón Cofiño41, Vera Ortiz-Santamaria42, Santos Castañeda43, Maria Laino44, Carmen Ordás Calvo45, Celia arconada46, ana Urruticoechea-Arana47, Blanca Garcia-Magallon48, Ana Valeria Acosta Alfaro49, Samuel Leal Rodriguez50, Marina Salido Olivares7, Patricia Lavilla Villar51, Anahy Maria Brandy3, Inmaculada Ros Vilamajo52, Alvaro García Martos53, Berta Magallares54, Guillen Sada Urmeneta55, Cristina Córdoba Martín56, Elena Riera Alonso57, Carmen Bejerano-Herreria58 and Ricardo Blanco,<58, 1Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 2Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain, 3Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 4Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, 5Hospital Universitario Doctor Peset, Valencia, Spain, 6Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, 7Hospital Clínico San Carlos, Madrid, Spain, 8Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, 9Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, 10Department of Rheumatology, Hospital Universtiario de Móstoles, Madrid, Spain, Madrid, Madrid, Spain, 11Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, 12Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, 13Hospital Central de La Defensa Gómez Ulla, Madrid, Madrid, Spain, 14Hospital Universitario de Torrevieja, Alicante, Spain, 15Hospital Universitario Vall D'Hebron, Barcelona, Spain, 16Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, 17Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, 18Hospital Universitario Infanta Leonor, Madrid, Spain, 19Hospital Provincial de Pontevedra, Pontevedra, Spain, 20Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain, 21Hospital de Mérida, Badajoz, Spain, 22Hospital Universitario de Torrejón, Madrid, Spain, 23Hospital General de La Rioja, Logroño, Spain, 24Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 25Hospital Galdakao, Vizcaya, Spain, 26Rheumatology.Hospital Galdakao, Vizcaya, Pais Vasco, Spain, 27Hospital de Calahorra, Calahorra, Spain, 28Hospital Marina Baixa, PALMA DE MALLORCA, Spain, 29Rheumatology. Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, 30Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, 31Hospital General de Segovia, Segovia, Spain, 32Hospital Universitario del Henares, Madrid, Spain, 33Hospital de Barbastro, Huesca, Spain, 34Hospital Universitario Puerta del Mar, Cadiz, Spain, 35Hospital de Sagunto, Valencia, Spain, 36Hospital Verge de la Cinta, Tortosa, Tarragona, Spain, 37Complejo Hospitalario de Jaén, Jaén, Spain, 38Hospital Universitario Lucus Augusti, Lugo, Spain, 39Complejo Asistencial de Zamora, Zamora, Spain, 40Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 41Hospital Santa Bárbara, Soria, Spain, 42Hospital General de Granollers, Barcelona, Spain, 43Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 44Hospital Universitario de Navarra, Pamplona, Spain, 45Hospital Universitario de Cabueñes, Gijón, Spain, 46Hospital universitario de Getafe, Getafe, Madrid, Spain, 47Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, 48Rheumatology, Hospital Universitario Puerta de Hierro, Madrid, Spain, 49Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, 50Hospital Universitario La Fe, Valencia, Valencia, Spain, 51Hospital General de Villalba, Collado Villalba, Madrid, Spain, 52Hospital Son Llàtzer, Palma de Mallorca, Spain, 53Hospital del Tajo, Aranjuez, Madrid, Spain, 54Hospital de Sant Pau, Barcelona, Spain, 55Rheumatology, Hospital Reina Sofía, Tudela, Spain, 56Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Tenerife, Spain, 57Hospital Universitari Mùtua Terrassa, Terrassa, Spain, 58Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.

    Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody that binds to the type I interferon receptor subunit 1 (IFNAR1). ANI was approved by Spanish authorities…
  • Abstract Number: 1529 • ACR Convergence 2025

    Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE

    Georg Schett1, David Simon2, Margrit Wiesendanger3, Anca Askanase4, Vikas Majithia5, Neil Kramer6, Jacques Morel7, Philip J. Mease8, Ellen De Langhe9, Amit Saxena10, dominique Farge11, Alain Lescoat12, Alisha Desai13, Griff McTume14, Whitney Handy14, Sharmila Das13, Jerill Thorpe14, Alexis Melton14, Ashley Koegel14 and Emily Littlejohn15, 1Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 2Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4Columbia University Medical Center, New York, NY, 5Mayo Clinic Hospital, Jacksonville, FL, 6Overlook Medical Center; Atlantic Medical Group, Atlantic Health System, Summit, NJ, 7CHU and University of Montpellier, Montpellier, France, 8Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 9University Hospitals Leuven, Leuven, Belgium, 10Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, 11Hôpital Saint-Louis, Paris, France, 12CHU Rennes University Hospital, Rennes, France, 13Bristol Myers Squibb, Princeton, NJ, 14Bristol Myers Squibb, Princeton, 15Cleveland Clinic, Cleveland, OH

    Background/Purpose: BMS-986353 (CC-97540; CD19 NEX-T) is a CD19-directed chimeric antigen receptor (CAR) T cell therapy that expresses the same CAR as lisocabtagene maraleucel (liso-cel); it…
  • Abstract Number: 1511 • ACR Convergence 2025

    Mental Health and Medical Burden:  The Impact of Depression on Length of Stay in Lupus Patients

    Sophia Chang Stauffer1, Huan Chang2, Parth Desai3, Elaine Adams4, William Galanter5 and Axi Patel6, 1Mount Sinai Hospital, Sinai Urban Health Institute and Univ.of Illinois @ Chicago, Dept Medicine, Div. Endocrinology, Chicago, IL, 2University of Illinois at Chicago, Div Rheumatology and Jesse Brown VA Medical Center, Chicago, IL, 3University of Texas Southwestern Medical Center, Dallas, TX, 4Jesse Brown VA Medical Center, Chicago, IL, 5University of Illinois at Chicago, Division of General Internal Medicine, Chicago, IL, 6University of Illinois at Chicago, Div Rheumatology, Chicago, IL

    Background/Purpose: Depression is more common in patients with systemic lupus erythematosus (SLE) than in the general population. Individuals with SLE and a mental health condition…
  • Abstract Number: 1488 • ACR Convergence 2025

    Limited Concordance Between anti-dsDNA Assays and Association with Lupus Nephritis

    Jessica Dai1, Peter Izmirly2, Jill Buyon3 and H Michael Belmont4, 1New York University Grossman School of Medicine, Tenafly, NJ, 2New York University Grossman School of Medicine, New York, NY, 3NYU Grossman School of Medicine, New York, NY, 4NYU School of Medicine, New York, NY

    Background/Purpose: Anti-dsDNA antibodies are a key diagnostic marker of systemic lupus erythematosus (SLE), often associated with active disease. Its presence is detected using various commercial…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology